ArticleBMC cancer2026

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

Rosa Tambaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.